Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
999 Views
eMediNexus Editorial 22 December 2022
Despite advancements in the therapeutics of liver disease, portal-systemic encephalopathy is still challenging for clinicians because of the heterogeneity of neuropsychiatric symptoms, numerous risk factors, and the complexity of gaining a sustained response. The present study evaluated the efficacy of L-Ornithin, L-Aspartate contrasted with lactulose in Mexican patients with hyperammonemic hepatic encephalopathy. It randomized 20 patients to receive either lactulose or L-ornithine - L-aspartate for two weeks.
The study observed-
This study shows that the oral administration of lactulose or L-ornithine - L-aspartate to patients with cirrhosis and hyperammonemic encephalopathy significantly reduces serum ammonia levels, along with improving mental status parameters, number connection test, asterixis scores, and EEG activity.
Poo JL, Góngora J, Sánchez-Avila F, Aguilar-Castillo S, García-Ramos G, Fernández-Zertuche M, Rodríguez-Fragoso L, Uribe M. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann Hepatol. 2006 Oct-Dec;5(4):281-8. PMID: 17151582.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}